ReviewLeukemia2022
Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape.
Review in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- The efficacy of extracorporeal photopheresis in the treatment of steroid refractory acute graft-versus-host disease: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.Bone marrow transplantation · 2024Pooled it
- Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial.Nature communications · 2026Trial
- Extracorporeal photopheresis-New insights into an old procedure.Transfusion medicine (Oxford, England) · 2026Trial
- Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease.Annals of hematology · 2026Article
- Real-world outcomes in refractory chronic graft-Haematologica · 2026Article
- Chronic graft-versus-host disease.Nature reviews. Disease primers · 2026Review
- Advances in Cell Therapy for Chronic Graft-versus-Host Disease: Prophylactic and Therapeutic Perspectives.Clinical and experimental medicine · 2026Review
- Extracorporeal photopheresis therapy for graft-versus-host disease with atypical neurological manifestations: a case report.Annals of hematology · 2026Article
- Mammalian target of rapamycin inhibitors as the treatment for steroid-refractory acute graft-vs.-host disease after allogeneic hematopoietic stem cell transplantation: A systematic review and individual patient data meta-analysis.Experimental and therapeutic medicine · 2026Article
- Extracorporeal photopheresis alone or in combination with ruxolitinib for the treatment of chronic graft-versus-host disease.Frontiers in immunology · 2026Article
- Editorial: Allo-HSCT: novel clinical applications and therapeutic strategies in adults and analysis of rare procedure complications.Frontiers in immunology · 2026Article
- Safe and Efficient Extracorporeal Photopheresis in Patients with Pre-Procedure Hematocrit below 26.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2026Article
- Ruxolitinib Plus Extracorporeal Photopheresis for Steroid-Refractory Acute and Chronic Graft-Versus-Host Disease.Journal of clinical medicine research · 2025Article
- Treatment patterns of extracorporeal photopheresis in steroid-refractory graft versus host disease: A delphi study.Bone marrow transplantation · 2025Article
- Extracorporeal Photopheresis: From Animal Models to Clinical Practice.Transplantation direct · 2025Article
- Lower incidence of chronic graft-Haematologica · 2025Article
- Extracorporeal photopheresis therapy rapidly changes the cytokine profile and tumor microenvironment in cutaneous T cell lymphoma.Frontiers in immunology · 2025Article
- Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with steroid-refractory graft-versus-host disease (GvHD) are known to have a poor prognosis and for decades no approved drug has been available to treat this serious condition. Although ruxolitinib, a selective Janus kinase (JAK)1/2 inhibitor demonstrated significantly higher response rates in randomized trials compared to the best available therapy, and thus, is of benefit in both acute as well as chronic GvHD, there is an urgent medical need to improve results, such as durability of responses, response in eye, liver and lung manifestations and reduction of infectious complications. In this "Review" article we would like to offer strategies for improving treatment results in patients with steroid-refractory GvHD by combining ruxolitinib with extracorporeal photopheresis (ECP), a leukapheresis-based immunomodulatory treatment frequently applied in T-cell mediated immune disease including GvHD. Our article explores key published evidence supporting the clinical efficacy of both ruxolitinib and ECP in the treatment of GvHD and highlights their potentially complementary mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.